Cargando…

End of season 2022/2023 quadrivalent influenza vaccine effectiveness in preventing influenza in primary care in Portugal

Using a test-negative case–control design, we aim to estimate influenza vaccine effectiveness (VE) against medically attended laboratory-confirmed influenza in Portugal in 2022/2023 season. Between week 41/2022 and week 14/2023, data on 592 patients with influenza-like illness aged 18 or more years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kislaya, Irina, Torres, Ana Rita, Gomes, Licínia, Melo, Aryse, Machado, Ausenda, Henriques, Camila, Verdasca, Nuno, Guiomar, Raquel, Rodrigues, Ana Paula, Surveillance Network, National Influenza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653732/ https://www.ncbi.nlm.nih.gov/pubmed/37964588 http://dx.doi.org/10.1080/21645515.2023.2263219

Ejemplares similares

Monitoring COVID-19 and Influenza: The Added Value of a Severe Acute Respiratory Infection Surveillance System in Portugal
por: Torres, Ana Rita, et al.
Publicado: (2023)

Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April–June 2022
por: Kislaya, Irina, et al.
Publicado: (2023)

Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023
por: Kissling, Esther, et al.
Publicado: (2023)

Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons
por: Machado, Ausenda, et al.
Publicado: (2019)

Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population
por: Machado, Ausenda, et al.
Publicado: (2019)

Performance of surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018
por: Sáez-López, Emma, et al.
Publicado: (2019)

Excess pneumonia and influenza hospitalizations associated with influenza epidemics in Portugal from season 1998/1999 to 2014/2015
por: Rodrigues, Emanuel, et al.
Publicado: (2018)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Excess Mortality Associated with Influenza Epidemics in Portugal, 1980 to 2004
por: Nunes, Baltazar, et al.
Publicado: (2011)

Avian influenza overview December 2022 – March 2023
por: Adlhoch, Cornelia, et al.
Publicado: (2023)

Influenza Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Cases and Hospitalizations in Navarre, Spain, 2022–2023
por: Martínez-Baz, Iván, et al.
Publicado: (2023)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022
por: Kislaya, Irina, et al.
Publicado: (2022)

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
por: Tisa, V., et al.
Publicado: (2016)

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season
por: Moss, Stephen, et al.
Publicado: (2023)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018
por: Boikos, Constantina, et al.
Publicado: (2020)

Monitoring of SARS-CoV-2 Specific Antibodies after Vaccination
por: Guiomar, Raquel, et al.
Publicado: (2022)

Influenza surveillance during 2015/2016 season in Portugal
por: Guiomar, R., et al.
Publicado: (2016)

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control
por: Ray, Riju, et al.
Publicado: (2017)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
por: Jamotte, Aurélien, et al.
Publicado: (2016)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Epidemiology and prevention of influenza in children in Argentina and Brazil
por: Argentinean Influenza Brazilian Working Group Vaccine,
Publicado: (2017)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Interim Estimates of 2022–23 Seasonal Influenza Vaccine Effectiveness — Wisconsin, October 2022–February 2023
por: McLean, Huong Q., et al.
Publicado: (2023)

Relative Effectiveness of the Cell-derived Inactivated Quadrivalent Influenza Vaccine Versus Egg-derived Inactivated Quadrivalent Influenza Vaccines in Preventing Influenza-related Medical Encounters During the 2018–2019 Influenza Season in the United States
por: Boikos, Constantina, et al.
Publicado: (2021)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

Will a Quadrivalent Vaccine Solve the Problem of Influenza B Mismatches?
por: Choi, Eun Hwa, et al.
Publicado: (2018)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia
por: Aljunid, Syed Mohamed, et al.
Publicado: (2023)

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
por: Thommes, Edward W., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k7mce68ouah1sp4o6j2v1s1o81